CAR T-Cell Therapy in Functional High-Risk Multiple Myeloma

Source link :

A subgroup analysis of the CARTITUDE-4 study, which was recently presented at the American Society of Clinical Oncology (ASCO) annual meeting, showed that ciltacabtagene autoleucel (cilta-cel; Carvykti) improved outcomes compared with standard of care among lenalidomide (Revlimid)-refractory patients with functional high-risk multiple myeloma. MedPage Today brought together three expert leaders in the field — moderator […]

Author : News Health

Publish date : 2024-06-27 14:58:09

Copyright for syndicated content belongs to the linked Source.